Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT.

N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.

2.

Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.

Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.

Allergy. 2013 Nov;68(11):1452-9. doi: 10.1111/all.12244. Epub 2013 Sep 21.

3.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.

Ann Allergy Asthma Immunol. 2011 Dec;107(6):529-37. doi: 10.1016/j.anai.2011.08.015. Epub 2011 Oct 5.

PMID:
22123383
4.

Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.

Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.

Clin Exp Immunol. 2014 Aug;177(2):544-53. doi: 10.1111/cei.12358.

5.

Management of acute attacks of hereditary angioedema: potential role of icatibant.

Longhurst HJ.

Vasc Health Risk Manag. 2010 Sep 7;6:795-802. Review.

6.

Icatibant.

Deeks ED.

Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000.

PMID:
20030426
7.

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.

Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.

Int Arch Allergy Immunol. 2015;168(1):44-55. doi: 10.1159/000441060. Epub 2015 Nov 11.

PMID:
26556097
8.

Icatibant for the treatment of hereditary angioedema.

Cole SW, Lundquist LM.

Ann Pharmacother. 2013 Jan;47(1):49-55. doi: 10.1345/aph.1R423. Epub 2012 Dec 18. Review.

PMID:
23249729
9.

Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.

Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR.

Allergy Asthma Proc. 2014 Sep-Oct;35(5):377-81. doi: 10.2500/aap.2014.35.3780. Epub 2014 Aug 6.

PMID:
25198193
10.

Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):245-7. Review.

PMID:
21284353
11.

A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

Baş M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK.

N Engl J Med. 2015 Jan 29;372(5):418-25. doi: 10.1056/NEJMoa1312524.

12.

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.

Campos RA, Valle SO, França AT, Cordeiro E, Serpa FS, Mello YF, Malheiros T, Toledo E, Mansour E, Fusaro G, Grumach AS.

Sao Paulo Med J. 2014;132(5):261-5. Epub 2014 Jul 22.

13.

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W.

J Allergy Clin Immunol. 2007 Jun;119(6):1497-503. Epub 2007 Apr 5.

PMID:
17418383
14.

Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.

Baş M.

Expert Rev Clin Immunol. 2012 Nov;8(8):707-17. doi: 10.1586/eci.12.67.

PMID:
23167682
15.
16.

Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.

Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbrán A.

Allergy. 2014 Mar;69(3):305-14. doi: 10.1111/all.12303.

17.

Icatibant for hereditary angioedema.

Gras J.

Drugs Today (Barc). 2009 Dec;45(12):855-64. doi: 1396674/dot.2009.45.12.1424267. Review.

PMID:
20135020
18.

Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.

Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, Maurer M, Fabien V, Aberer W, Bouillet L, Zanichelli A, Caballero T; IOS Study Group.

Int Arch Allergy Immunol. 2015;167(1):21-8. doi: 10.1159/000430864. Epub 2015 Jun 25.

20.

Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.

Krause K, Metz M, Zuberbier T, Maurer M, Magerl M.

J Dtsch Dermatol Ges. 2010 Apr;8(4):272-4. doi: 10.1111/j.1610-0387.2009.07215.x. Epub 2009 Sep 16. English, German.

PMID:
19758369
Items per page

Supplemental Content

Write to the Help Desk